Results 21 to 30 of about 22,960 (241)
Targeting Diet and Exercise for Neuroprotection and Neurorecovery in Glaucoma
Cells, 2021 Glaucoma is a leading cause of blindness worldwide. In glaucoma, a progressive dysfunction and death of retinal ganglion cells occurs, eliminating transfer of visual information to the brain. Currently, the only available therapies target the lowering of
James R. Tribble +6 more
doaj +1 more source
Personalizing Intraocular Pressure
Asia-Pacific Journal of Ophthalmology, 2016 Determining target intraocular pressure (IOP) in glaucoma patients is multifaceted, requiring attention to many different factors such as glaucoma type, severity of disease, age, race, family history, corneal thickness and hysteresis, and initial IOP.
Arthur J, Sit, Christopher M, Pruet
openaire +2 more sources
Endocannabinoid metabolism and transport as targets to regulate intraocular pressure
Experimental Eye Research, 2020 Cannabinoids are part of an endogenous signaling system found throughout the body, including the eye. Hepler and Frank showed in the early 1970s that plant cannabinoids can lower intraocular pressure (IOP), an effect since shown to occur via cannabinoid CB1 and GPR18 receptors. Endocannabinoids are synthesized and metabolized enzymatically.
Miller S +8 more
openaire +4 more sources
Journal of Ophthalmology, 2021 Background: Until now, no direct relationship has been established between the target pressure and particular corneal thickness for measurements with different types of tonometers.
Dmitriev S. K. +3 more
doaj +1 more source
Combined use of coenzyme Q10 and citicoline: A new possibility for patients with glaucoma
Frontiers in Medicine, 2022 Glaucoma is the leading cause of irreversible blindness worldwide. Several risk factors have been involved in the pathogenesis of the disease. By now, the main treatable risk factor is elevated intraocular pressure.
Alessio Martucci +5 more
doaj +1 more source
New Therapeutic Targets for Intraocular Pressure Lowering
ISRN Ophthalmology, 2013 Primary open-angle glaucoma (POAG) is a leading cause of irreversible and preventable blindness and ocular hypertension is the strongest known risk factor. With current classes of drugs, management of the disease focuses on lowering intraocular pressure (IOP). Despite of their use to modify the course of the disease, none of the current medications for
Rocha-Sousa, A. +6 more
openaire +2 more sources
The Outcomes of Bleb Revision Surgery Techniques After Trabeculectomy
Türk Oftalmoloji Dergisi, 2012 Pur po se: To evaluate the techniques and the results of revision surgeries in order to manage bleb failure after trabeculectomy. Ma te ri al and Met hod: The records of 23 eyes who had undergone bleb revision surgery because of bleb failure after ...
Orhan Ayar +5 more
doaj +1 more source
Therapeutic Advances in Ophthalmology, 2020 Background: Glaucoma is most common irreversible cause of blindness in India. First line management of open-angle glaucoma is either beta blockers or prostaglandin analogs monotherapy.
Alok Dixit, Atul Ashish, Reena Sharma
doaj +1 more source
Target IOP as a measure of glaucoma surgery efficacy
Oftalʹmologiâ, 2015 There are numerous criteria of glaucoma surgery efficacy. Among them, IOP level is of special importance. The development of tolerant and target IOP concepts as well as IOP tolerability issue are reviewed below.
S. Yu. Petrov
doaj +3 more sources
Türk Oftalmoloji Dergisi, 2012 Pur po se: To evaluate the effects of latanoprost/timolol maleate and dorzolamid/timolol maleate fixed combinations on-24 hours intraocular pressure in patients with open-angle glaucoma.
Berna Yüce +3 more
doaj +1 more source